CA3188446A1 - Eif4e-inhibiting 4-oxo-3,4-dihydropyrido[3,4-d]pyrimidine compounds - Google Patents
Eif4e-inhibiting 4-oxo-3,4-dihydropyrido[3,4-d]pyrimidine compoundsInfo
- Publication number
- CA3188446A1 CA3188446A1 CA3188446A CA3188446A CA3188446A1 CA 3188446 A1 CA3188446 A1 CA 3188446A1 CA 3188446 A CA3188446 A CA 3188446A CA 3188446 A CA3188446 A CA 3188446A CA 3188446 A1 CA3188446 A1 CA 3188446A1
- Authority
- CA
- Canada
- Prior art keywords
- alkyl
- compound
- mmol
- cancer
- haloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962869662P | 2019-07-02 | 2019-07-02 | |
| US62/869,662 | 2019-07-02 | ||
| PCT/US2020/040299 WO2021003157A1 (en) | 2019-07-02 | 2020-06-30 | Eif4e-inhibiting 4-oxo-3,4-dihydropyrido[3,4-d]pyrimidine compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3188446A1 true CA3188446A1 (en) | 2021-01-07 |
Family
ID=71614984
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3188446A Pending CA3188446A1 (en) | 2019-07-02 | 2020-06-30 | Eif4e-inhibiting 4-oxo-3,4-dihydropyrido[3,4-d]pyrimidine compounds |
| CA3085255A Pending CA3085255A1 (en) | 2019-07-02 | 2020-06-30 | Eif4e-inhibiting compounds and methods |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3085255A Pending CA3085255A1 (en) | 2019-07-02 | 2020-06-30 | Eif4e-inhibiting compounds and methods |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11286268B1 (enExample) |
| EP (1) | EP3994139A1 (enExample) |
| JP (1) | JP7595055B2 (enExample) |
| KR (1) | KR20220061945A (enExample) |
| CN (1) | CN114269756B (enExample) |
| AR (1) | AR119339A1 (enExample) |
| AU (1) | AU2020299362B2 (enExample) |
| BR (1) | BR112021026682A2 (enExample) |
| CA (2) | CA3188446A1 (enExample) |
| CL (1) | CL2021003573A1 (enExample) |
| IL (1) | IL289456A (enExample) |
| PY (1) | PY2031844A (enExample) |
| TW (1) | TWI748541B (enExample) |
| UY (1) | UY38773A (enExample) |
| WO (1) | WO2021003157A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3993875A4 (en) * | 2019-07-02 | 2023-08-02 | Effector Therapeutics, Inc. | METHODS OF TREATMENT OF BRAF MUTANT CANCER CELLS |
| WO2021127071A1 (en) * | 2019-12-18 | 2021-06-24 | Merck Sharp & Dohme Corp. | Bicyclic heterocycle compounds methods of use thereof for the treatment of herpes viruses |
| US20250243221A1 (en) * | 2020-05-27 | 2025-07-31 | Effector Therapeutics, Inc. | Covalent modifiers of eif4e inhibiting compounds |
| CN117337293A (zh) * | 2020-12-22 | 2024-01-02 | 弗埃塞股份有限公司 | 固体形式的eif4e抑制剂 |
| EP4615848A1 (en) * | 2022-11-10 | 2025-09-17 | Ribometrix, Inc. | Compounds and compositions as eif4e inhibitors and uses thereof |
| TW202428278A (zh) * | 2022-12-23 | 2024-07-16 | 大陸商南京聖和藥業股份有限公司 | 作為ｅＩＦ４Ｅ抑制劑的化合物及其應用 |
| AU2024316010A1 (en) | 2023-07-28 | 2026-02-05 | Cogent Biosciences, Inc. | Pi3k inhibitors |
| WO2025101516A1 (en) * | 2023-11-06 | 2025-05-15 | Ribometrix, Inc. | Methods of using eif4e inhibitors for treating cancer |
| WO2025120599A1 (en) * | 2023-12-08 | 2025-06-12 | Ribometrix, Inc. | METHODS OF USING eIF4E INHIBITORS FOR TREATING CANCER |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080255161A1 (en) * | 2007-04-11 | 2008-10-16 | Dmitry Koltun | 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS |
| US20110065671A1 (en) * | 2008-05-19 | 2011-03-17 | Harris Joel M | Bicyclic heterocycle derivatives and use thereof as gpr119 modulators |
| TW201412740A (zh) | 2012-09-20 | 2014-04-01 | Bayer Pharma AG | 經取代之吡咯并嘧啶胺基苯并噻唑酮 |
| WO2014179237A1 (en) * | 2013-04-29 | 2014-11-06 | Vanderbilt University | Substituted 3-benzylquinoxalin-4(3h)-one analogs as positive allosteric modulators of muscarinic acetycholine receptor m1 |
| US9993494B2 (en) | 2014-02-07 | 2018-06-12 | Effector Therapeutics, Inc. | Compositions and methods for treating fibrotic disease |
| TWI713455B (zh) | 2014-06-25 | 2020-12-21 | 美商伊凡克特治療公司 | ＭｎＫ抑制劑及其相關方法 |
-
2020
- 2020-06-30 CA CA3188446A patent/CA3188446A1/en active Pending
- 2020-06-30 JP JP2022500099A patent/JP7595055B2/ja active Active
- 2020-06-30 CN CN202080059936.5A patent/CN114269756B/zh active Active
- 2020-06-30 EP EP20740483.1A patent/EP3994139A1/en active Pending
- 2020-06-30 US US16/916,820 patent/US11286268B1/en active Active
- 2020-06-30 WO PCT/US2020/040299 patent/WO2021003157A1/en not_active Ceased
- 2020-06-30 TW TW109122116A patent/TWI748541B/zh active
- 2020-06-30 CA CA3085255A patent/CA3085255A1/en active Pending
- 2020-06-30 BR BR112021026682A patent/BR112021026682A2/pt unknown
- 2020-06-30 AU AU2020299362A patent/AU2020299362B2/en active Active
- 2020-06-30 KR KR1020227002902A patent/KR20220061945A/ko not_active Ceased
- 2020-07-02 UY UY0001038773A patent/UY38773A/es not_active Application Discontinuation
- 2020-07-02 PY PY202002031844A patent/PY2031844A/es unknown
- 2020-07-02 AR ARP200101877A patent/AR119339A1/es not_active Application Discontinuation
-
2021
- 2021-12-28 IL IL289456A patent/IL289456A/en unknown
- 2021-12-30 CL CL2021003573A patent/CL2021003573A1/es unknown
-
2022
- 2022-01-28 US US17/587,185 patent/US20230108594A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| PY2031844A (es) | 2021-04-19 |
| JP2022539256A (ja) | 2022-09-07 |
| KR20220061945A (ko) | 2022-05-13 |
| CL2021003573A1 (es) | 2022-08-12 |
| TW202115058A (zh) | 2021-04-16 |
| TWI748541B (zh) | 2021-12-01 |
| US20230108594A1 (en) | 2023-04-06 |
| EP3994139A1 (en) | 2022-05-11 |
| AR119339A1 (es) | 2021-12-09 |
| CN114269756B (zh) | 2024-05-14 |
| US11286268B1 (en) | 2022-03-29 |
| JP7595055B2 (ja) | 2024-12-05 |
| UY38773A (es) | 2021-01-29 |
| CA3085255A1 (en) | 2021-01-02 |
| CN114269756A (zh) | 2022-04-01 |
| AU2020299362B2 (en) | 2026-02-26 |
| BR112021026682A2 (pt) | 2022-03-15 |
| AU2020299362A1 (en) | 2022-02-24 |
| WO2021003157A1 (en) | 2021-01-07 |
| IL289456A (en) | 2022-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230108594A1 (en) | Eif4e-inhibiting compounds and methods | |
| TWI762579B (zh) | 六氫吡啶經取代之ＭｎＫ抑制劑及其相關方法 | |
| US9669031B2 (en) | MNK inhibitors and methods related thereto | |
| JP7406674B2 (ja) | スピロ環化合物 | |
| JP6892444B2 (ja) | Ｍｎｋ１およびｍｎｋ２のイソインドリン、アザイソインドリン、ジヒドロインデノンならびにジヒドロアザインデノン阻害薬 | |
| TWI824309B (zh) | 作為PI3K-γ抑制劑之雜環化合物 | |
| KR102677015B1 (ko) | Bet 억제제로서의 헤테로시클릭 화합물 | |
| CN117304191A (zh) | 作为a2a/a2b抑制剂的稠合吡嗪衍生物 | |
| JP6888006B2 (ja) | Ｍｎｋ１およびｍｎｋ２を阻害するピロロ−、ピラゾロ−、イミダゾ−ピリミジンおよびピリジン化合物 | |
| US10662186B2 (en) | Substituted pyrimidines as cyclin-dependent kinase inhibitors | |
| AU2012245344A1 (en) | Aminopyrimidine kinase inhibitors | |
| CN113330014B (zh) | 抑制mnk1和mnk2的多环化合物 | |
| US12435063B2 (en) | Nitrogen containing heterocycles as CDK12 inhibitors | |
| JP2022526831A (ja) | ヘテロ環式化合物およびその使用 | |
| CN121991092A (zh) | 三并环类衍生物抑制剂、其制备方法和应用 | |
| HK40043646A (en) | Heterocyclic compound | |
| HK40043646B (en) | Heterocyclic compound |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241106 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20241107 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250407 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250507 |
|
| P22 | Classification modified |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED Effective date: 20250625 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250702 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20251103 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251106 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251106 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251217 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20251230 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20251230 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20251230 |